2023
Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance
Maheswaranathan M, Miller B, Ung N, Sinha R, Harrison C, Egeli B, Degirmenci H, Sirotich E, Liew J, Grainger R, Chock E. Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance. Clinical Rheumatology 2023, 43: 543-552. PMID: 37552351, DOI: 10.1007/s10067-023-06717-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19FemaleHumansMaleMiddle AgedPandemicsRheumatic DiseasesRheumatologyTelemedicineConceptsRheumatic diseasesPerson visitsTelemedicine useMedication changesCOVID-19 pandemicCare of patientsPerspectives of patientsMethodsAn anonymous online surveyPerspectives of telemedicineDisease activityComplete responseMost patientsPatient's perspectiveTelemedicine effectivenessPatientsAnonymous online surveyFree-text responsesSimilar effectivenessDiseaseVisitsTelemedicine usersRheumatologyYounger participantsTelemedicineClinical tasks
2022
Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status
Maguire S, Al-Emadi S, Alba P, Aguiar M, Al Lawati T, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez K, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu T, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich D, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel N, Pera M, Pisoni C, Pons-Estel G, Quiambao A, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales R, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner M, Wise L, Worthing A, Zell J, Zepa J, Machado P, Yazdany J, Robinson P, Conway R. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status. Rheumatology 2022, 62: 1621-1626. PMID: 36124987, PMCID: PMC11181869, DOI: 10.1093/rheumatology/keac534.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 TestingCOVID-19 VaccinesFemaleHumansInfant, NewbornPregnancyPremature BirthRheumatic DiseasesVaccinationConceptsObstetric outcomesPreterm birthVaccination statusPregnant womenUnvaccinated womenCOVID-19Exact testCOVID-19 vaccination statusCOVID-19 vaccine dosesCOVID-19 vaccinationCOVID-19 infectionFisher's exact testCOVID-19 diagnosisVaccine doseHospital admissionRheumatic diseasesMore dosesVaccine dosesPharmacological treatmentMusculoskeletal diseasesPregnancyDescriptive studyWomenOutcomesGreater numberBaseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Rider L, Parks C, Wilkerson J, Schiffenbauer A, Kwok R, Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche M, Levine M, Sattui S, Liew J, Harrison C, Moni T, Miller A, Putman M, Hausmann J, Simard J, Sparks J, Miller F, Akpabio A, Alpizar-Rodriguez D, Berenbaum F, Bulina I, Conway R, Singh A, Duff E, Durrant K, Gheita T, Hill C, Howard R, Hoyer B, Hsieh E, Kibbi L, Kilian A, Kim A, Liew D, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee C, Singh J, Singh N, Ugarte-Gil M, Wallace J, Young K, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Foster G, Thabane L, Angevare S, Beesley R, Chock E, Degirmenci B, Felix C, Jin S, Mateus E, Peirce A, Sari E, Tseng R, Wang L, Zamora E. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology 2022, 61: si143-si150. PMID: 35460240, PMCID: PMC9248066, DOI: 10.1093/rheumatology/keac249.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19COVID-19 VaccinesFemaleHumansMaleProspective StudiesRheumatic DiseasesSelf ReportSymptom Flare UpVaccinationConceptsSystemic rheumatic diseasesCOVID-19 vaccinationRisk factorsDisease flareRheumatic diseasesHigher oddsSARS-CoV-2 severityFlare of diseaseIdiopathic inflammatory myopathiesSystemic lupus erythematosusOxford-AstraZeneca vaccineMultivariable logistic regressionHistory of reactionPotential risk factorsPfizer-BioNTech vaccineLarge international studyImmunosuppressive medicationsInternational studiesVaccines surveyAdverse eventsInflammatory myopathiesPolymyalgia rheumaticaProspective cohortPsoriatic arthritisBaseline factorsSARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedRegistriesRheumatic DiseasesRheumatologySARS-CoV-2ConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung disease
2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedRheumatic DiseasesRheumatologySARS-CoV-2Surveys and QuestionnairesVaccinationConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritisCOVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bermas B, Gianfrancesco M, Tanner H, Seet A, Aguiar M, Al Adhoubi N, Al Emadi S, Cunha B, Flood R, Kusevich D, McCarthy E, Patel N, Ruderman E, Sattui S, Sciascia S, Siddique F, Valenzuela-Almada M, Wise L, Worthing A, Zell J, Bhana S, Costello W, Duarte-Garcia A, Grainger R, Gossec L, Hausmann J, Hyrich K, Lawson-Tovey S, Liew J, Sirotich E, Sparks J, Sufka P, Wallace Z, Machado P, Strangfeld A, Clowse M, Yazdany J, Robinson P. COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance. The Journal Of Rheumatology 2021, 49: 110-114. PMID: 34470798, DOI: 10.3899/jrheum.210480.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19COVID-19 TestingFemaleHumansInfant, NewbornMiddle AgedPregnancyPregnant WomenRheumatic DiseasesRheumatologySARS-CoV-2Young AdultConceptsRheumatic diseasesPregnant womenPregnancy outcomesObstetric detailsCOVID-19Combination of antimalarialsRheumatic disease diagnosisLopinavir/ritonavirSystemic lupus erythematosusCases of patientsCOVID-19 infectionCoronavirus disease 2019Time of infectionCOVID-19 diagnosisTime of reportAntiphospholipid syndromeInflammatory arthritidesPreterm birthLupus erythematosusMedian ageTerm birthsRheumatoid arthritisSupplemental oxygenArthritis/Medication treatmentAssociation of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Gianfrancesco M, Leykina L, Izadi Z, Taylor T, Sparks J, Harrison C, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Hsu T, D’Silva K, Serling‐Boyd N, Wallwork R, Todd D, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J, Alliance T. Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry. Arthritis & Rheumatology 2021, 73: 374-380. PMID: 33146001, PMCID: PMC8467766, DOI: 10.1002/art.41567.Peer-Reviewed Original ResearchConceptsRheumatic diseasesGeneral US populationRace/ethnicityVentilatory supportLatinx patientsOdds ratioUS populationCOVID-19Rheumatic disease activityRheumatic disease diagnosisOdds of hospitalizationAfrican American patientsAssociation of raceCOVID-19 outcomesPhysician registryCoronavirus disease 2019COVID-19 hospitalizationMultivariable regression modelsSignificant health disparitiesNeeds of patientsInequitable health outcomesDisease activityHospitalized patientsMedication useWhite patientsFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Strangfeld A, Schäfer M, Gianfrancesco M, Lawson-Tovey S, Liew J, Ljung L, Mateus E, Richez C, Santos M, Schmajuk G, Scirè C, Sirotich E, Sparks J, Sufka P, Thomas T, Trupin L, Wallace Z, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann J, Hyrich K, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson P, Yazdany J, Machado P, Dahou B, Pinheiro M, Ribeiro F, Chassin-Trubert A, Ibáñez S, Dong L, Cajas L, Hamoud H, Avouac J, Belin V, Borie R, Chazerain P, Chevalier X, Claudepierre P, Clavel G, Colette-Cedoz M, Combe B, Constant E, Costedoat-Chalumeau N, Desmurs M, Devauchelle-Pensec V, Devaux M, Dhote R, Dieudonné Y, Domont F, Duret P, Ebbo M, Ebstein E, Mahou S, Fautrel B, Felten R, Flipo R, Foltz V, Froissart A, Galland J, Gaud-Listrat V, Georgin-Lavialle S, Giraud-Morelet A, Quitrec J, Goupille P, Govindaraju-Audouard S, Grados F, Guillaume-Czitrom S, Hermet M, Hittinger-Roux A, Hudry C, Kone-Paut I, La Batide Alanore S, Lafforgue P, Lahalle S, Lambrecht I, Langlois V, Larbre J, Ledoult E, Leroux C, Liote F, Maria A, Marotte H, Mekinian A, Melki I, Messer L, Michel C, Morel G, Morel J, Paris-Havard M, Pertuiset E, Pham T, Renard M, Revuz S, Rivière S, Rousselin C, Roux C, Rouzaud D, Sellam J, Seror R, Servettaz A, Sobanski V, Sordet C, Spielmann L, Tieulié N, Tison A, Trijau S, Virone A, Warzocha U, Wendling D, Albach F, Aries P, Decker E, Hartmann U, Henes J, Hoyer B, Krause A, Krüger K, Lorenz H, Müller-Ladner U, Pfeil A, Regierer A, Richter J, Rihl M, Schmeiser T, Schulze-Koops H, Specker C, Voll R, Werner S, Melgar G, Vojdanian, Andreoli L, Bartoloni-Bocci E, Benucci M, Campanaro F, Caprioli M, Carboni D, Carrara G, Cipolletta E, Crotti C, Dallagiacoma G, Faggioli P, Foti R, Franceschini F, Fredi M, Guidelli G, Iannone F, Landolfi G, Lomater C, Nalli C, Parisi S, Quartuccio L, Raffeiner B, Reggia R, Riva M, Romeo N, Rotondo C, Silvagni E, Sinigaglia L, Tinazzi I, Zanetti A, Zanframundo G, Abutiban F, Alpízar-Rodríguez D, Rull-Gabayet M, Irazoque F, Jimenez X, Martín-Nares E, Castillo-Ortiz A, Rodriguez-Reyna T, Rosete D, Zamora-Tehozol E, Vega-Morales D, Zaueta-Montiel B, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Almeida D, Bernardes M, Machado R, Rato M, Al-Emadi S, Conway R, Flood R, Alegre-Sancho J, Coro M, de la Torre-Rubio N, Esteban J, del Martin M, Puerta J, Back J, Dastmalchi M, Dupré B, Grenholm E, Hensvold A, Knight A, Akar S, Icacan O, Chadwick L, Devine K, Dunt S, Fusi L, Jones C, Macphie E, Nikiphorou E, O'Kane D, O'Reilly S, Patel S, Salerno R, Thornton L, Tyler J, Vandevelde C, Warner E, Yeoh S, Baig S, Bajwa H, Ban B, Berglund V, Calabrese C, D'Silva K, Dahle A, Dao K, Daver N, Davis W, Dorman W, Fatemeh E, Fields T, Hargrove J, Harvey M, Hilton M, Hsu T, Izadi Z, Jayatilleke A, Karp D, Kepecs G, Kramer N, Lamore C, Lebedoff N, Leonard S, Mody S, Morgan J, Pfeifer E, Quiceno G, Quinet R, Rosenstein E, Ruderman E, Scopelitis E, Serling-Boyd N, Siddique F, Skemp A, Sparks J, Todd D, Toribio K, Wallwork R, Webb-Detiege T, White D, Wilson J, Winter M, Wise L, Wolff A, Young K, Zakem J, Zell J, Zimmerman K. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2021, 80: 930-942. PMID: 33504483, PMCID: PMC7843211, DOI: 10.1136/annrheumdis-2020-219498.Peer-Reviewed Original ResearchConceptsDisease-modifying anti-rheumatic drugsCOVID-19-related deathsHigh disease activityRheumatic diseasesDisease activityHigher oddsBiological disease-modifying anti-rheumatic drugsMultivariable logistic regression modelRegistry of adultsRheumatic disease diagnosisAnti-rheumatic drugsChronic lung diseaseDisease-specific factorsAdequate disease controlLogistic regression modelsGlucocorticoid dosageMethotrexate monotherapyPrimary outcomeSmoking statusMale sexLung diseaseCardiovascular diseaseIndependent factorsDisease categoriesDisease control
2020
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice
Liew J, Bhana S, Costello W, Hausmann J, Machado P, Robinson P, Sirotich E, Sufka P, Wallace Z, Yazdany J, Grainger R, Alliance F. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology 2020, 60: 353-358. PMID: 32789449, PMCID: PMC7454885, DOI: 10.1093/rheumatology/keaa483.Peer-Reviewed Original ResearchCharacteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased oddsThe Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance
Wallace Z, Bhana S, Hausmann J, Robinson P, Sufka P, Sirotich E, Yazdany J, Grainger R. The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology 2020, 59: 1204-1206. PMID: 32374851, PMCID: PMC7239169, DOI: 10.1093/rheumatology/keaa191.Peer-Reviewed Original Research